Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial Comparing Induction Chemotherapy With Cisplatin/5-fluorouracil (PF) or Docetaxel/Cisplatin/5-fluorouracil (TPF) Plus Chemoradiotherapy (CRT) Versus CRT Alone as First-line Treatment or Unresectable Locally Advanced Head and Neck Cancer (LAHNC).

NCT00261703 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00261703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00261703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial Comparing Induction Chemotherapy With Cisplatin/5-fluorouracil (PF) or Docetaxel/Cisplatin/5-fluorouracil (TPF) Plus Chemoradiotherapy (CRT) Versus CRT Alone as First-line Treatment or Unresectable Locally Advanced Head and Neck Cancer (LAHNC).
Lead sponsor
Sanofi
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2002
Completion date
July 31, 2010
Enrollment
439 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck neoplasms